414 related articles for article (PubMed ID: 24591761)
1. Molecular markers for breast cancer: prediction on tumor behavior.
Banin Hirata BK; Oda JM; Losi Guembarovski R; Ariza CB; de Oliveira CE; Watanabe MA
Dis Markers; 2014; 2014():513158. PubMed ID: 24591761
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
McFall T; McKnight B; Rosati R; Kim S; Huang Y; Viola-Villegas N; Ratnam M
J Biol Chem; 2018 Jan; 293(4):1163-1177. PubMed ID: 29162724
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study.
Marino AL; Evangelista AF; Vieira RA; Macedo T; Kerr LM; Abrahão-Machado LF; Longatto-Filho A; Silveira HC; Marques MM
BMC Cancer; 2014 Oct; 14():739. PubMed ID: 25277099
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs in breast cancer pathogenesis.
Götte M
Minerva Ginecol; 2010 Dec; 62(6):559-71. PubMed ID: 21079577
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer.
Bertoli G; Cava C; Castiglioni I
Theranostics; 2015; 5(10):1122-43. PubMed ID: 26199650
[TBL] [Abstract][Full Text] [Related]
6. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
Canevari RA; Marchi FA; Domingues MA; de Andrade VP; Caldeira JR; Verjovski-Almeida S; Rogatto SR; Reis EM
Tumour Biol; 2016 Oct; 37(10):13855-13870. PubMed ID: 27485113
[TBL] [Abstract][Full Text] [Related]
8. Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer.
Saleh AA; Soliman SE; Habib MSE; Gohar SF; Abo-Zeid GS
Mol Biol Rep; 2019 Jun; 46(3):2809-2818. PubMed ID: 30835039
[TBL] [Abstract][Full Text] [Related]
9. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs as Biomarker for Breast Cancer.
Aggarwal T; Wadhwa R; Gupta R; Paudel KR; Collet T; Chellappan DK; Gupta G; Perumalsamy H; Mehta M; Satija S; Hansbro PM; Dua K; Maurya PK
Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1597-1610. PubMed ID: 32342824
[TBL] [Abstract][Full Text] [Related]
11. Biomolecular features of clinical relevance in breast cancer.
Daidone MG; Paradiso A; Gion M; Harbeck N; Sweep F; Schmitt M
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S3-14. PubMed ID: 15095022
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.
Swellam M; Ramadan A; El-Hussieny EA; Bakr NM; Hassan NM; Sobeih ME; EzzElArab LR
J Cell Biochem; 2019 Aug; 120(8):12321-12330. PubMed ID: 30825229
[TBL] [Abstract][Full Text] [Related]
13. The Role of MicroRNAs in Diagnosis, Prognosis, Metastasis and Resistant Cases in Breast Cancer.
Teoh SL; Das S
Curr Pharm Des; 2017; 23(12):1845-1859. PubMed ID: 28231756
[TBL] [Abstract][Full Text] [Related]
14. The potential of miRNAs for diagnosis, treatment and monitoring of breast cancer.
Bertoli G; Cava C; Castiglioni I
Scand J Clin Lab Invest Suppl; 2016; 245():S34-9. PubMed ID: 27435502
[TBL] [Abstract][Full Text] [Related]
15. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC
Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026
[TBL] [Abstract][Full Text] [Related]
16. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
[TBL] [Abstract][Full Text] [Related]
17. The miR-30 family: Versatile players in breast cancer.
Yang SJ; Yang SY; Wang DD; Chen X; Shen HY; Zhang XH; Zhong SL; Tang JH; Zhao JH
Tumour Biol; 2017 Mar; 39(3):1010428317692204. PubMed ID: 28347244
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in carcinogenesis, progression and therapy of breast cancer: the 20th Hiroshima Cancer Seminar--the 4th Three Universities' Consortium International Symposium, October 2010: 31 October 2010, International Conference Center Hiroshima.
Toi M; Yasui W; Ito H; Tahara E
Jpn J Clin Oncol; 2011 Jul; 41(7):924-30. PubMed ID: 21565925
[TBL] [Abstract][Full Text] [Related]
19. Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction.
Kashyap D; Kaur H
Life Sci; 2020 Apr; 246():117417. PubMed ID: 32044304
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
